Stellar Biotechnologies, Inc. to Present at Two Investor Conferences in January
06 Januar 2014 - 3:05PM
Marketwired
Stellar Biotechnologies, Inc. to Present at Two Investor
Conferences in January
PORT HUENEME, CA--(Marketwired - Jan 6, 2014) - Stellar
Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF)
(TSX-VENTURE: KLH) announced today that the Company will present at
two upcoming investor conferences in January: the Biotech Showcase
2014 in San Francisco and the Noble Financial Capital Markets Tenth
Annual Equity Conference in South Florida.
Frank Oakes, Stellar's President and CEO will present at both
conferences, providing an overview of the Company, its programs and
milestones, and 2014 corporate objectives. Members of Stellar's
executive team will be available for meetings at both events.
Biotech Showcase™ 2014 Date and Time: January 14, 2014, 4:00 PM
PST Venue Location: Parc 55 Wyndham San Francisco, CA Conference
Website: http://www.ebdgroup.com/bts/index.php
Noble Financial Capital Markets Tenth Annual Equity Conference
Date and Time: January 21, 2014, 8:00 AM EST Venue Location: Club
Med Sandpiper Bay, Sandpiper Bay, Florida Conference Website:
http://www.nobleresearch.com/TEN/2014.htm
Presentation schedules and details will be posted on Stellar's
website at
http://stellarbiotechnologies.com/investors/profile_presentations/
About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (TSX-VENTURE: KLH) (OTCQB: SBOTF)
is the world leader in sustainable manufacture of Keyhole Limpet
Hemocyanin (KLH), an important immune-stimulating protein used in
wide-ranging therapeutic and diagnostic markets. KLH is both an
active pharmaceutical ingredient (API) in many new immunotherapies
(targeting cancer, infectious diseases, and immune disorders) as
well as a finished product for measuring immune status. Stellar
Biotechnologies is unique in its proprietary methods, facilities,
and KLH technology. We are committed to meeting the growing demand
for commercial-scale supplies of GMP grade KLH, ensuring
environmentally sound KLH production, and developing KLH-based
active immunotherapies.
To receive regular updates, enter email at
http://stellarbiotechnologies.com/contact/
Visit www.StellarBiotech.com and the KLH knowledge base
www.KLHSite.com.
Forward Looking Statements There can be no assurance that
forward-looking statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such statements. Readers should not place undue
reliance on such statements. Except in accordance with applicable
securities laws, the Company expressly disclaims any obligation to
update any forward-looking statements or forward-looking statements
that are incorporated by reference herein. This news release does
not constitute an offer to sell, or a solicitation of an offer to
buy any of the Company's securities set out herein in the United
States, or to, or for the benefit or account of, a U.S. Person or
person in the United States. Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of these releases.
Stellar Biotechnologies, Inc. (TSXV:KLH)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Stellar Biotechnologies, Inc. (TSXV:KLH)
Historical Stock Chart
Von Jan 2024 bis Jan 2025
